September 12th 2024
The trial showcased the continued efficacy of apremilast, with 2-year data on the forefront.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
'Sensitive skin' a dilemma for derms:How do you treat what you can't see?
May 1st 2004Maui, Hawaii - While complaints of "sensitive skin" may be challenging to address, dermatologists can frequently help patients obtain relief, even if there are no overt clinical manifestations to treat, according to Patricia G. Engasser, M.D.
Low-strength tacrolimus eases atopic dermatitis
May 1st 2004Washington - Results from two multicenter, randomized, double-blind trials demonstrate that tacrolimus ointment 0.03 percent (Protopic) is a safe and effective treatment for mild to moderate atopic dermatitis in pediatric patients and adults.
FDA accepts Connetics Corp. NDA filing for Extina
April 8th 2004Source: www.PRNewswire.com Connetics Corp., a specialty pharmaceutical company focused on dermatology announced Thursday, April 8 that it has received confirmation that the FDA has accepted for filing the company's NDA for Extina, as of Jan. 26, 2004, with a user fee goal date of Sept. 24, 2004.
Early eczema control linked to allergies, asthma
April 1st 2004Waikoloa, Hawaii - If eczema can be kept under better control during infancy and early childhood, it might be possible to reduce the atopic march and lessen the development of asthma and allergies in some children, said Adelaide A. Hebert, M.D. Topical immune modulators could play a role in keeping the skin barrier more intact and reducing a child's propensity to develop a high level of atopic diseases, added Dr. Hebert, professor and vice chairman, department of dermatology, University of Texas Health Science Center, Houston.
New pediatric therapies emerging
April 1st 2004Washington -- New therapies continue to emerge in pediatric dermatology, and recent studies demonstrate the effectiveness of such therapies. Ilona J. Frieden, M.D., highlighted studies in some areas of common concern in a presentation at the annual meeting of the American Academy of Dermatology.
Newer May Not Always Be Better
April 1st 2004About 15 years ago, while riding on a shuttle bus at the annual American Academy of Dermatology meeting, I overheard two elderly dermatologists discussing the state of dermatology, as they perceived it. One gentleman commented that he had not seen a single advance to rival the advent of tetracycline for acne, and that most of the new treatments did not work very well. At the time, I remember thinking that these practitioners were out of touch with all of the hot new therapies for skin disorders. Since that time, as I have been bombarded by myriad new and supposedly revolutionary "advances," I, too, am beginning to question whether we should equate the concept of "newness"